STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

Carbetocin

Also known as

Pabal · Duratocin · long-acting oxytocin analog

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Niche talk Systemic IV / IM; nasal (trial) Reproductive & endocrine peptides

Systemic — an oxytocin analogue used IV/IM after childbirth; intranasal PWS research is a separate route and indication.

What people say Carbetocin is a systemic synthetic long-acting oxytocin analogue, not a cytomedine. It is used medically as an IV/IM postpartum uterotonic; intranasal carbetocin has been investigated separately in Prader–Willi syndrome. Doses people talk about
Obstetric product-information dose100 micrograms IV or IM once

IV after cesarean delivery; IV or IM after vaginal delivery, in monitored postpartum care.

COMPASS PWS investigational regimen3.2 mg intranasal three times daily for 12 weeks

Phase 3 research regimen; efficacy endpoints did not separate from placebo and this is not an approved self-use protocol.

These amounts are not interchangeable and do not form a self-use progression.

Half-life & effect duration

Half-life in the body
  • IV · terminal clearanceAbout 41 minutes
Felt duration people report
  • Nasal trial accountsBehavior changes across treatment, sometimes most apparent after stopping
  • After one doseNo consistent duration reported
Timing context & sources
How it may feel Some PWS caregivers perceived less food preoccupation, anxiety or behavioral difficulty, despite the negative randomized trial. Obstetric adverse-event reports arise in a different, heavily confounded childbirth setting.
Cycles people discuss Obstetric use is a one-time clinician-administered dose, not a recurring course. COMPASS PWS studied intranasal use for 12 weeks; after the negative efficacy result, the sponsor announced plans to discontinue its open-label extension. Timing Obstetric administration is tied to completed childbirth in monitored care. The separate PWS trial used repeated intranasal doses across the day; neither context supplies a mood-use or restart schedule. Stacks Obstetric comparisons with oxytocin or additional uterotonics belong to monitored medical care. The checked sources do not establish a nootropic or mood stack. Watch for Medical-label adverse effects: Obstetric trials list nausea, abdominal pain, pruritus, flushing, vomiting, warmth, hypotension, headache, or tremor; surgery, anesthesia, and childbirth complicate attribution. Use before delivery is contraindicated.
Related
OxytocinPT-141

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

Official product information reports a mean terminal elimination half-life of 41 minutes.

The same source reports 41 ± 11.9 minutes and a distribution half-life of 5.5 ± 1.6 minutes.

Study dose and nonpregnant population differ from the 100-microgram obstetric dose; it does not establish intranasal kinetics or subjective duration.

  • Duratocin — Australian Product Information (opens in a new tab)Duratocin PI: §4.2 p.1 dose/route; §4.3 pp.1–2 contraindications; §4.8 pp.4–5 adverse effects; §5.1 p.6 uterine response; §5.2 pp.9–10 PK.Country- and product-specific labeling; the overall PK program involved 25 healthy nonpregnant women across IV/IM doses, while the obstetric dosing context is 100 micrograms.

Felt duration people report

No dependable single-dose felt window is established for intranasal carbetocin in the reviewed PWS sources.

Caregivers perceived behavioral changes across the trial, sometimes most apparent after stopping, without a reliable onset-to-baseline interval. The obstetric uterine response is a different pharmacodynamic endpoint.

Small, retrospective caregiver feedback cannot establish efficacy or a causal individual clock; the randomized trial was negative.

Other context in this card

  • COMPASS PWS Results Community Letter (opens in a new tab)One-page September 24, 2025 community letter: the study did not meet primary or secondary endpoints and the sponsor announced plans to discontinue the open-label extension.Sponsor/community communication rather than proof of later execution or a full statistical report; use alongside the peer-reviewed abstract.
  • Carbetocin for preventing postpartum haemorrhage (opens in a new tab)Background pharmacology section of the systematic review: IV contraction within two minutes, initial tetanic response followed by rhythmic contraction for about one hour; IM response followed by rhythmic contraction for about two hours.Systematic review background synthesizes pharmacokinetic and pharmacodynamic studies; durations are uterine endpoints, not subjective sensations or intranasal PWS timing.

What people say 5

  • Caregiver perspective: In a small caregiver feedback effort after COMPASS PWS, some families perceived less anxiety or food preoccupation and social or cognitive changes. These retrospective impressions are not proof of efficacy. anecdote
  • Obstetric evidence: Product information and trials support carbetocin as a uterotonic for prevention of uterine atony and excessive bleeding after childbirth in specified clinical settings. trial
  • What is established: Obstetric evidence includes randomized comparisons summarized in official product information; this is not a thin peptide-brand literature. trial
  • Investigational PWS result: In the phase 3 COMPASS PWS study, intranasal 3.2 mg three times daily for 12 weeks did not separate from placebo on the primary, secondary, or exploratory efficacy endpoints. trial
  • Time-course boundary: Obstetric uterine contraction begins within minutes and lasts roughly one to two hours depending on route; intranasal PWS efficacy was assessed across 12 weeks and did not show separation from placebo. trial

Doses people talk about 4

  • Medical single dose: The reviewed Australian Duratocin information describes 100 micrograms IV after cesarean delivery, or 100 micrograms IV or IM after vaginal delivery, as one clinician-administered postpartum dose. trial
  • Separate investigational context: COMPASS PWS studied intranasal carbetocin 3.2 mg three times daily for 12 weeks. That milligram nasal regimen is not comparable to the one-time obstetric microgram dose and is not an endorsed self-use protocol. trial
  • Not chronic obstetric use: The approved obstetric context is a one-time postpartum dose, not daily peptide self-use. trial
  • Obstetric framing: Official product information describes carbetocin for prevention of uterine atony and excessive bleeding following childbirth in specified settings; treatment of established postpartum hemorrhage is a different question. trial

How it may feel 5

  • Caregiver reports: Some caregivers described perceived behavior, anxiety, food-preoccupation, social, or cognitive changes during the 12-week PWS trial, while the randomized efficacy analyses remained negative. anecdotetrial
  • Obstetric administration: IV or IM carbetocin acts within minutes on uterine contraction. Nausea, abdominal pain, pruritus, flushing, vomiting, warmth, hypotension, headache, or tremor appear in product information, with childbirth, surgery, and anesthesia complicating attribution. trial
  • Obstetric course: The reviewed product information describes a one-time clinician-administered postpartum dose, not a recurring 10–20-day bioregulator course. trial
  • Immediate pharmacodynamic window: Product information reports uterine contraction within about two minutes, lasting about one hour after IV administration and about two hours after IM administration. This is not a mood-effect clock. trial
  • Intranasal PWS study: The phase 3 program evaluated repeated intranasal dosing over 12 weeks; it did not establish a typical single-dose subjective effect lasting two to seven days. trial

Cycles people discuss 4

  • Program outcome: After COMPASS PWS missed its efficacy endpoints, the sponsor announced plans to discontinue the open-label extension; caregiver concerns about the 12-week window are perspectives, not proof that a longer cycle would work. forumtrial
  • Obstetric use: The reviewed product information describes one clinician-administered postpartum dose; seasonal or repeated courses do not apply. trial
  • Clinical boundary: Obstetric dosing occurs in monitored medical care, where adverse effects and postpartum bleeding require clinical assessment; this profile does not supply a stop-or-restart rule. trial
  • PWS research duration: COMPASS PWS used repeated intranasal administration for 12 weeks. This was a clinical-trial period, not a validated on/off cycle for general use. trial

Timing 3

  • Measured IV pharmacokinetics: A PK program involved 25 healthy nonpregnant women across IV/IM doses. At 400 micrograms IV, reported distribution and terminal half-lives were 5.5 ± 1.6 and 41 ± 11.9 minutes, respectively. trial
  • Pharmacodynamic duration: Uterine contraction begins within about two minutes and lasts about one hour after IV administration or about two hours after IM administration; this differs from plasma elimination half-life and subjective mood effects. trial
  • Intramuscular context: The same product information reports an IM peak at about 20–30 minutes and approximately 80% bioavailability. These data do not establish intranasal PWS kinetics or a subjective felt window. trial

More on what it is 5

  • How people talk about it: Some Prader–Willi caregivers reported perceived day-to-day changes despite the negative overall trial; those observations are important community context but do not overturn the randomized result. forumtrial
  • What it is: Carbetocin is a synthetic long-acting oxytocin analogue and agonist, not a Khavinson-style cytomedine or organ-targeted bioregulator. Medical products use it as a uterotonic after childbirth. trial
  • Evidence honesty: Obstetric use is documented in product information and randomized trials. A separate 175-participant intranasal phase 3 Prader–Willi syndrome trial found no separation from placebo on primary, secondary, or exploratory efficacy endpoints. trial
  • Two contexts: Obstetric IV/IM microgram use and investigational intranasal milligram dosing answer different clinical questions and cannot be compared as one route, amount, or felt clock. trial
  • Medical boundary: Obstetric carbetocin is clinician-administered. Intranasal carbetocin for Prader–Willi syndrome was investigational in the reviewed phase 3 program and is not a self-experimentation protocol. trial

Stacks 2

  • Attribution: The original personal n=1 versus five-compound comparison is a general attribution warning, not evidence for a carbetocin mood stack. Obstetric co-medications belong to monitored care. forumtrial
  • Obstetric co-treatment context: Trials and product information compare carbetocin with oxytocin or describe additional uterotonics when clinically needed; this is not a multi-bioregulator stack. trial

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 6

  • Allergy / unknown impurities: Gray-market risk. forum
  • Route-specific safety: Redness, itch, lumps and bruising remain generic injection concerns, with technique and product quality relevant; they do not establish a carbetocin self-injection route. Official use here is clinician-administered IV/IM, with label adverse effects described separately. forumtrial
  • Unknowns: Long-term safety for gray-market preparations is often poorly characterized. forum
  • Stack noise: Sides logged on multi-agent stacks cannot be blamed cleanly on one compound. forum
  • Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice. forum
  • Medical-label adverse effects: Obstetric trials list nausea, abdominal pain, pruritus, flushing, vomiting, warmth, hypotension, headache, or tremor; surgery, anesthesia, and childbirth complicate attribution. Use before delivery is contraindicated. trial

Updated: 2026-08-12

Evidence mix More trial/lab tags than forum tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →